The multiple facets of drug resistance: one history, different approaches
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Some cancers like melanoma and pancreatic and ovarian cancers, for example, commonly display resistance to chemotherapy, and this is the major obstacle to a better prognosis of patients. Frequently, literature presents studies in monolayer cell cultures, 3D cell cultures or in vivo studies, but rarely the same work compares results of drug resistance in different models. Several of these works are presented in this review and show that usually cells in 3D culture are more resistant to drugs than monolayer cultured cells due to different mechanisms. Searching for new strategies to sensitize different tumors to chemotherapy, many methods have been studied to understand the mechanisms whereby cancer cells acquire drug resistance. These methods have been strongly advanced along the years and therapies using different drugs have been increasingly proposed to induce cell death in resistant cells of different cancers. Recently, cancer stem cells (CSCs) have been extensively studied because they would be the only cells capable of sustaining tumorigenesis. It is believed that the resistance of CSCs to currently used chemotherapeutics is a major contributing factor in cancer recurrence and later metastasis development. This review aims to appraise the experimental progress in the study of acquired drug resistance of cancer cells in different models as well as to understand the role of CSCs as the major contributing factor in cancer recurrence and metastasis development, describing how CSCs can be identified and isolated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 2×
“01-1% of total tumor cells) first described in leukemia and then in breast cancer and others solid tumors [16,17,146,147].”
BackgroundCellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 4×
“The most commonly used surface markers are CD44+ and CD133+ [17,146].”
BackgroundInfluentialTaking Cell-Matrix Adhesions to the Third Dimension
Cukierman, E., Pankov, R., Stevens, D. R., & Yamada, K. M. (2001) · Science · doi:10.1126/science.1064829 · Cited by 3,027 · cited 1×
“increases cell interactions with other cells and with the ECM, which is closer to in vivo conditions [116,117].”
BackgroundMulticellular tumor spheroids: An underestimated tool is catching up again
Hirschhaeuser, F., Menne, H., Dittfeld, C., West, J., Mueller-Klieser, W., & Kunz-Schughart, L. A. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.01.012 · Cited by 1,674
Frisch, S. M., & Screaton, R. A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00251-9 · Cited by 1,249
Loessner, D., Stok, K. S., Lutolf, M. P., Hutmacher, D. W., Clements, J. A., & Rizzi, S. C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.07.064 · Cited by 602 · cited 1×
“[139,140].”
Cited by
Cell membrane modulation as adjuvant in cancer therapy
Zalba, S., & ten Hagen, T. L. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.008 · Cited by 365
Zhang, S., Yang, Y., Weng, W., Guo, B., Cai, G., Ma, Y., & Cai, S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0985-y · Cited by 316
Yin, Y., Yao, S., Hu, Y., Feng, Y., Li, M., Bian, Z., Zhang, J., Qin, Y., Qi, X., Zhou, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1283 · Cited by 296
“In addition, as chemotherapy usually induces acquired chemoresistance of cancer cells, the surviving cancer cells after chemotherapy often display MDR phenotypes (28).”
BackgroundHe, J., Zhou, M., Chen, X., Yue, D., Yang, L., Qin, G., Zhang, Z., Gao, Q., Wang, D., Zhang, C., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0378-z · Cited by 85
Xu, J., Xiong, G., Cao, Z., Huang, H., Wang, T., You, L., Zhou, L., Zheng, L., Hu, Y., Zhang, T., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0406-z · Cited by 53
“Cancer cells present different mechanisms of drug resistance including innate mechanisms that result in modulation of intracellular signaling pathways [31].”
Metadata
- Authors
- Niero, E. L., Rocha-Sales, B., Lauand, C., Cortez, B. A., de Souza, M. M., Rezende-Teixeira, P., Urabayashi, M. S., Martens, A. A., Neves, J. H., & Machado-Santelli, G. M.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2014-04-28
- Volume
- 33
- Issue
- 1
- Pages
- 37-37
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W2102275220
- Cited by
- 137
- References
- 16
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The multiple facets of drug resistance: one history, different approaches. https://app.cochat.ai/papers/10.1186/1756-9966-33-37
- The paper
- Niero, E. L., Rocha-Sales, B., Lauand, C., Cortez, B. A., de Souza, M. M., Rezende-Teixeira, P., Urabayashi, M. S., Martens, A. A., Neves, J. H., & Machado-Santelli, G. M. (2014). The multiple facets of drug resistance: one history, different approaches. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/1756-9966-33-37
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.